Cargando…
CYP2C19 Genotyping May Provide a Better Treatment Strategy when Administering Escitalopram in Chinese Population
Depression disorder is one of the most serious mental illnesses in the world. Escitalopram is the essential first-line medication for depression disorder. It is the substrate of hepatic cytochrome P450 (CYP) enzyme CYP2C19 with high polymorphism. The effect of CYP2C19 on pharmacokinetics and pharmac...
Autores principales: | Huang, Xinyi, Li, Chao, Li, Chaopeng, Li, Zhenyu, Li, Xiaohui, Liao, Jianwei, Rao, Tai, Chen, Lulu, Gao, Lichen, Ouyang, Dongsheng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8429954/ https://www.ncbi.nlm.nih.gov/pubmed/34512354 http://dx.doi.org/10.3389/fphar.2021.730461 |
Ejemplares similares
-
Escitalopram Personalized Dosing: A Population Pharmacokinetics Repository Method
por: Liu, Xin, et al.
Publicado: (2023) -
Population pharmacokinetics model for escitalopram in Chinese psychiatric patients: effect of CYP2C19 and age
por: Liu, Shujing, et al.
Publicado: (2022) -
CYP2C19 polymorphisms and outcomes of Escitalopram treatment in Brazilians with major depression
por: Bernini de Brito, Rodrigo, et al.
Publicado: (2020) -
PS105. Effects of CYP2C19 genotype on steady-state plasma concentrations of escitalopram and desmetyl metabolite in Japanese depressed patients
por: Tsuchimine, Shoko, et al.
Publicado: (2016) -
Two Single Nucleotide Polymorphisms (rs2431697 and rs2910164) of miR-146a Are Associated with Risk of Coronary Artery Disease
por: Wang, Yaqin, et al.
Publicado: (2017)